MINYANVILLE ORIGINAL Shares of Bristol-Myers Squibb (NYSE:BMY) are rising after the drug maker won US approval for Eliquis its blood-thinning treatment aimed at preventing strokes and serious blood clots. Bristol-Myers and development partner Pfizer (NYSE:PFE) got word of the approval Friday afternoon almost three months earlier than a deadline set by the Food and Drug Administration. The FDA rejected the drug last June saying the companies needed to provide more information to show the medicine works and is safe. Eliquis is an alternative to warfarin which has been used for decades. Other companies including Johnson & Johnson (NYSE:JNJ) and ...